Since end of September 2020 curasan AG is a non-listed stock corporation. Curasan AG is a leading German manufacturer in regenerative medicine. Our stypro hemostyptic is used in major Chinese hospitals in surgery and dentistry. Stypro offers fast hemostasis , has a high absorbent potential up to 35 times of its own weight, has optimal porosity and interconnection and is resorbable and implantable. It is available in different sizes to fit the needs of different surgical departments. curasan´s innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. Numerous patents and a broad record of scientific publications demonstrate the clinical success of curasan´s highly innovative products. As exclusive distribution partner in China, Beijing Bicom Tc Company presents curasan´s innovative solutions for tissue enigineering, wound healing and hemostasis.
stypro ® has:
a high capacity of absorption of liquids (up to 35 times its weight)
a rapid haemostatic effect
an optimal interconnecting porosity
an excellent tolerance and biocompatibility, no exogenous thrombin is needed